"At Zimbis, we're driven by the opportunity to make complex operations simpler for dental laboratories," said Louis Visser, President Zimbis. "By partnering with Argen, we're giving labs access to ...

The antibody experts at arGEN-X have teamed up with dermatology-focused biotech Leo Pharma on a treatment for inflammatory skin diseases, inking a deal worth up to $116 million. Under the agreement, ...

arGEN-X, a clinical stage biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody therapeutics, announces that it has progressed its ...

The facility will operate under arGEN-X’ CSO Prof. Dr. Hans de Haard, and CDO Dr. Torsten Dreier, who have already attracted an experienced international core team of antibody discovery and ...

ARGEN is a patented light scattering instrument that addresses key research and development issues in the biopharmaceutical industry by providing real-time stability monitoring, manufacturing stress ...

RuiYi (formerly Anaphore) negotiated a worldwide exclusive license to ArGEN-X’ preclinical anti-IL-6 monoclonal antibody ARGX-109, which is in development as a potential treatment for oncology and ...

LONDON – "This window really is unique: It's supporting relatively early stage stories and especially platform technology stories." So said Tim Van Hauwermeiren, CEO of antibody specialist Argen-x BV, ...

Firm will combine fucose-removal technology with in-house camelid-based Simple platform for therapeutic antibodies. arGEN-X negotiated a nonexclusive license to BioWa’s Potelligent® monoclonal ...

CYPRESS, Texas—Argen Polymer L.L.C., a specialist in materials development, consulting, testing and analysis, just announced three new advances for the company: • ISO accreditation in January 2017, ...

AM CETAmsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving ...